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Background
Mucin 1 (MUC1), a glycoprotein normally expressed at
low levels on the apical borders of secretory epithelial
cells, is overexpressed and aberrantly glycosylated in many
cancers. ONT 10 is a therapeutic peptide vaccine incor-
porating a synthetic glycolipopeptide MUC1 antigen,
M40Tn6, and novel synthetic TLR-4 agonist, PET Lipid A,
in a liposomal formulation designed to elicit antibody and
cellular immune responses.
Methods
A phase 1 study was initiated to evaluate the safety and
tolerability of ONT-10, as well as cellular and humoral
immune responses and antitumor activity. Patients (pts)
with incurable solid tumors associated with MUC1
expression were eligible. Cyclophosphamide 250 mg/m2
IV was given on day -3 followed by ONT-10 at the
cohort-specific dose (250 µg, 500 µg or 1000 µg) subcuta-
neously day 1 and then Q2W for 4 total doses or QW for
8 total doses in a 3+3 dose escalation design. Immune
response was assessed by serum titers of MUC1-specific
antibodies using M40Tn6 ELISA and by MUC1-specific
ELISPOT for interferon gamma. Tumor response was
assessed by RECIST 1.1 and immune-related response
criteria (irRC). Pts without progressive disease by irRC
were eligible for a maintenance protocol to receive ONT-
10 every 6 weeks.
Results
The study is ongoing and 28 pts have been treated. Diag-
noses were: ovarian/primary peritoneal (n=10), pancreatic
(n=5), colorectal (n=3), endometrial (n=3), breast (n=2),
lung, bladder, cervical, duodenal, and prostate (n=1 each).
Median prior lines of therapy 4 (range 1 - 11); median age
61.5 years (range 35 - 77); all pts had ECOG status of 0/1.
No DLTs have occurred at doses up to 1000 µg Q2W and
500 μg QW. 90% of AEs have been Grade 1-2; the most
common (≥20%) being fatigue (40%), abdominal pain
(28%), nausea (28%) and constipation (24%). The most
common treatment-related AEs (TRAEs) have been fatigue
(32%) and injection site reactions (20%) and all TRAEs
have been Grade 1-2. MUC1 specific antibody responses
were seen in the majority of pts. Cellular response assess-
ment is ongoing. Best tumor response in 25 evaluable pts
was SD (17 pts; 68%) and PD (8 pts; 32%). One pt with
ovarian cancer had 16% tumor shrinkage. SD ≥ 6 mo was
seen in 28% of patients including ovarian/primary perito-
neal (n=3) and endometrial, breast, colon, pancreatic (n=1
each). 17 pts have enrolled on the maintenance study.
Conclusions
In a diverse population of late stage cancer pts, ONT-10
was well tolerated at up to 1000 µg Q2W and 500 µg QW.
Prolonged disease control and encouraging immune
responses have been seen. Updated results and immune
data will be presented.
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